Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients
BACKGROUND: Low-dose tacrolimus-based immunosuppression is a standard therapy in kidney and liver transplantation; however, the optimal therapeutic level of tacrolimus has not been established in lung transplantation. We aimed to identify the tacrolimus level associated with better outcomes in lung...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Annals of Thoracic Medicine |
Subjects: | |
Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=186;epage=191;aulast=Ryu |
id |
doaj-de62eb4104dd4fdfa83cfe78e8663a1e |
---|---|
record_format |
Article |
spelling |
doaj-de62eb4104dd4fdfa83cfe78e8663a1e2020-11-24T23:53:20ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572019-01-0114318619110.4103/atm.ATM_160_18Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patientsJung-Hwa RyuSunmi ChoiHyun Joo LeeYoung Tae KimYoung Whan KimJaeseok YangBACKGROUND: Low-dose tacrolimus-based immunosuppression is a standard therapy in kidney and liver transplantation; however, the optimal therapeutic level of tacrolimus has not been established in lung transplantation. We aimed to identify the tacrolimus level associated with better outcomes in lung transplant patients. METHODS: This retrospective study included patients who underwent lung transplantation at Seoul National University Hospital between 2006 and 2016. Kaplan–Meier survival analysis and Cox regression were performed according to tacrolimus levels at several time-points within 1-year posttransplantation. RESULTS: A total of 43 patients received bilateral lung transplantation. The median age was 53 years and the median follow-up was 20.5 months. Overall and 1-year patient survival rates were 55.8% and 74.4%, respectively. Infection was the most common cause of death (78.9%). Chronic lung allograft dysfunction was observed in 16.3%. A tacrolimus level <9 ng/ml at 1 month was associated with lower rejection-free survival (P = 0.009). A time-averaged tacrolimus level <10 ng/ml within 1 month posttransplantation was an independent risk factor for poor patient survival (hazard ratio: 4.904; 95% confidence interval: 1.930–12.459; P= 0.001). Furthermore, higher tacrolimus levels did not increase infectious complications. CONCLUSIONS: These finding suggest that tacrolimus levels ≥10 ng/ml within 1 month after lung transplantation appear to be associated with better patient survival.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=186;epage=191;aulast=RyuChronic lung allograft dysfunctionlung transplantationrejectionsurvivaltacrolimus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jung-Hwa Ryu Sunmi Choi Hyun Joo Lee Young Tae Kim Young Whan Kim Jaeseok Yang |
spellingShingle |
Jung-Hwa Ryu Sunmi Choi Hyun Joo Lee Young Tae Kim Young Whan Kim Jaeseok Yang Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients Annals of Thoracic Medicine Chronic lung allograft dysfunction lung transplantation rejection survival tacrolimus |
author_facet |
Jung-Hwa Ryu Sunmi Choi Hyun Joo Lee Young Tae Kim Young Whan Kim Jaeseok Yang |
author_sort |
Jung-Hwa Ryu |
title |
Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients |
title_short |
Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients |
title_full |
Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients |
title_fullStr |
Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients |
title_full_unstemmed |
Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients |
title_sort |
low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients |
publisher |
Wolters Kluwer Medknow Publications |
series |
Annals of Thoracic Medicine |
issn |
1817-1737 1998-3557 |
publishDate |
2019-01-01 |
description |
BACKGROUND: Low-dose tacrolimus-based immunosuppression is a standard therapy in kidney and liver transplantation; however, the optimal therapeutic level of tacrolimus has not been established in lung transplantation. We aimed to identify the tacrolimus level associated with better outcomes in lung transplant patients.
METHODS: This retrospective study included patients who underwent lung transplantation at Seoul National University Hospital between 2006 and 2016. Kaplan–Meier survival analysis and Cox regression were performed according to tacrolimus levels at several time-points within 1-year posttransplantation.
RESULTS: A total of 43 patients received bilateral lung transplantation. The median age was 53 years and the median follow-up was 20.5 months. Overall and 1-year patient survival rates were 55.8% and 74.4%, respectively. Infection was the most common cause of death (78.9%). Chronic lung allograft dysfunction was observed in 16.3%. A tacrolimus level <9 ng/ml at 1 month was associated with lower rejection-free survival (P = 0.009). A time-averaged tacrolimus level <10 ng/ml within 1 month posttransplantation was an independent risk factor for poor patient survival (hazard ratio: 4.904; 95% confidence interval: 1.930–12.459; P= 0.001). Furthermore, higher tacrolimus levels did not increase infectious complications.
CONCLUSIONS: These finding suggest that tacrolimus levels ≥10 ng/ml within 1 month after lung transplantation appear to be associated with better patient survival. |
topic |
Chronic lung allograft dysfunction lung transplantation rejection survival tacrolimus |
url |
http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=186;epage=191;aulast=Ryu |
work_keys_str_mv |
AT junghwaryu lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients AT sunmichoi lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients AT hyunjoolee lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients AT youngtaekim lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients AT youngwhankim lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients AT jaeseokyang lowearlyposttransplantserumtacrolimuslevelsareassociatedwithpoorpatientsurvivalinlungtransplantpatients |
_version_ |
1725470291700744192 |